Daewoong Pharmaceutical

Daewoong Pharmaceutical

Daewoong Pharmaceutical was established in 2002 following the separation of production and sales operations from the broader Daewoong Group. Yoon Jae-seung, the current Chief Vision Officer and largest shareholder of the holding company, oversees the corporate investment program. The firm maintains manufacturing and research facilities in Hwaseong-si and Seoul. The investment program covers pharmaceuticals, biotechnology, and healthcare IT. Positions include direct ownership of iN Therapeutics at 93.9 percent, CGBio at 55.84 percent through Bluenet, and a joint venture in Affyxell Therapeutics. Public holdings comprise a 30.85 percent stake in Hanall Biopharma valued at approximately $691 million and a 4.85 percent position in Evolus. Activity spans South Korea and the United States, with additional exposure through Vincere Biosciences. The firm employs no disclosed headcount figure for its investment team. It maintains a foundation established in 1984 that supports medical research and scholarships. In October 2025 the firm sponsored CPHI Worldwide in Frankfurt, presenting on microneedle drug delivery and biosimilar technologies. Ownership flows through the family-controlled holding company Bluenet for selected private investments, creating a layered structure that separates listed pharmaceutical operations from venture and regenerative-medicine holdings.